Aadi Bioscience Gestione

Gestione criteri di controllo 2/4

Aadi Bioscience Il CEO è Dave Lennon, nominato in Oct2023, e ha un mandato di 1.08 anni. la retribuzione annua totale è $ 2.14M, composta da 7.5% di stipendio e 92.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.093% delle azioni della società, per un valore di € 50.00K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 3.3 anni.

Informazioni chiave

Dave Lennon

Amministratore delegato

US$2.1m

Compenso totale

Percentuale dello stipendio del CEO	7.5%
Mandato del CEO	1.1yrs
Proprietà del CEO	0.09%
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dave Lennon rispetto agli utili di Aadi Bioscience?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$62m
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$160k	-US$66m

Compensazione vs Mercato: La retribuzione totale di Dave ($USD 2.14M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 474.54K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Dave con le performance aziendali.

AMMINISTRATORE DELEGATO

Dave Lennon (53 yo)

1.1yrs

Mandato

US$2,135,687

Compensazione

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
David Lennon	President	1.1yrs	US$2.14m	0.093% € 50.0k
Scott Giacobello	CFO, Treasurer	3yrs	US$1.97m	0% € 0
Stephen Rodin	Senior VP of Legal & General Counsel	2.8yrs	Nessun dato	Nessun dato
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	2.4yrs	Nessun dato	Nessun dato
Bryan Ball	Chief Technical Operations Officer	2.3yrs	Nessun dato	0.41% € 218.6k

2.4yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 3350 è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Lennon	President	1.1yrs	US$2.14m	0.093% € 50.0k
Caley Castelein	Independent Chairman of the Board	3.3yrs	US$258.91k	0.080% € 43.1k
Emma Reeve	Independent Director	3.2yrs	US$240.91k	0% € 0
Anupam Dalal	Independent Director	3.3yrs	US$235.91k	0.0046% € 2.5k
Karin Hehenberger	Independent Director	3.3yrs	US$227.41k	0% € 0
Richard Maroun	Independent Director	7.8yrs	US$240.91k	0% € 0
Mohammad Hirmand	Independent Director	1.7yrs	US$345.60k	0% € 0
Behzad Aghazadeh	Independent Director	3.3yrs	US$225.41k	0% € 0

3.3yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 3350 sono considerati esperti (durata media dell'incarico 3.3 anni).

Aadi Bioscience Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Aadi Bioscience, Inc. Announces Executive Changes

High number of new directors

High number of new directors

High number of new directors

Aadi Bioscience, Inc. Announces Management Changes

Recent updates

Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023)

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Market cap size

Aadi Bioscience, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$0.87 loss in 2Q 2022)

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

High number of new directors

High number of new directors

High number of new directors

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$9.17 loss in 3Q 2021)

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Now 21% undervalued

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.22 loss in 2Q 2021)

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

High number of new directors

First quarter 2022 earnings released: US$0.66 loss per share (vs US$0.71 loss in 1Q 2021)

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

Interim Chief Financial Officer Lance Thibault has left the company

Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

No independent directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media